NCT04687241View on ClinicalTrials.gov

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

July 8, 2024

Study Completion Date

January 1, 2029

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Almonertinib

The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.

DRUG

Placebo Almonertinib

Placebo Almonertinib

Trial Locations (1)

130000

Jilin Province Cancer Hospital, Changchun

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

NCT04687241 - Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations | Biotech Hunter | Biotech Hunter